Filtros de búsqueda

Lista de obras de

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma

artículo científico publicado en 2014

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

artículo científico publicado en 2017

C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy

artículo científico publicado en 2017

Chemotherapy-free induction in MCL: ready for prime time?

scientific article published on 01 November 2018

Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival

artículo científico publicado en 2014

Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.

artículo científico publicado en 2016

Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin

artículo científico publicado en 2018

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

artículo científico publicado en 2015

Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients

artículo científico publicado en 2015

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes ⬇️

artículo científico publicado el 25 de julio de 2013

Ibrutinib treatment improves T cell number and function in CLL patients

artículo científico publicado en 2017

Jumping translocations, a novel finding in chronic lymphocytic leukaemia

artículo científico publicado en 2015

Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia

scientific article published on 15 August 2018

Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data

artículo científico publicado en 2020

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

artículo científico publicado en 2014

Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)

artículo científico publicado en 2015

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

artículo científico publicado en 2015

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era

scientific article published on 07 January 2019

The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

artículo científico publicado en 2015

Update on Mantle Cell Lymphoma

scientific article published on 28 August 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda